Indiva Past Earnings Performance
Past criteria checks 0/6
Indiva's earnings have been declining at an average annual rate of -3.6%, while the Pharmaceuticals industry saw earnings growing at 26.2% annually. Revenues have been growing at an average rate of 51.9% per year.
Key information
-3.6%
Earnings growth rate
9.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 51.9% |
| Return on equity | -1,870.0% |
| Net Margin | -19.3% |
| Next Earnings Update | 25 Apr 2024 |
Recent past performance updates
Recent updates
Indiva Limited (CVE:NDVA) Stock Catapults 33% Though Its Price And Business Still Lag The Industry
Sep 29
Is Indiva (CVE:NDVA) Using Debt In A Risky Way?
Sep 17Is Indiva (CVE:NDVA) A Risky Investment?
Apr 19Is Indiva (CVE:NDVA) Using Too Much Debt?
Feb 26Would Indiva (CVE:NDVA) Be Better Off With Less Debt?
Sep 04Would Indiva (CVE:NDVA) Be Better Off With Less Debt?
Nov 30Revenue & Expenses BreakdownBeta
How Indiva makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 36 | -7 | 12 | 1 |
| 30 Jun 23 | 34 | -9 | 12 | 1 |
| 31 Mar 23 | 35 | -10 | 12 | 1 |
| 31 Dec 22 | 34 | -11 | 13 | 1 |
| 30 Sep 22 | 34 | -12 | 13 | 1 |
| 30 Jun 22 | 34 | -16 | 13 | 1 |
| 31 Mar 22 | 35 | -15 | 13 | 1 |
| 31 Dec 21 | 32 | -15 | 11 | 0 |
| 30 Sep 21 | 30 | -18 | 10 | 0 |
| 30 Jun 21 | 25 | -15 | 10 | 0 |
| 31 Mar 21 | 19 | -16 | 8 | 0 |
| 31 Dec 20 | 15 | -15 | 8 | 0 |
| 30 Sep 20 | 8 | -11 | 7 | 0 |
| 30 Jun 20 | 5 | -10 | 6 | 0 |
| 31 Mar 20 | 3 | -10 | 7 | 0 |
| 31 Dec 19 | 1 | -11 | 9 | 0 |
| 30 Sep 19 | 1 | -11 | 10 | 0 |
| 30 Jun 19 | 0 | -10 | 10 | 0 |
| 31 Mar 19 | 0 | -10 | 9 | 0 |
| 31 Dec 18 | 0 | -9 | 7 | 0 |
| 30 Sep 18 | 0 | -7 | 6 | 0 |
| 30 Jun 18 | 0 | -6 | 5 | 0 |
| 31 Mar 18 | 0 | -5 | 3 | 0 |
| 31 Dec 17 | 0 | -3 | 2 | 0 |
| 30 Sep 17 | 0 | -2 | 2 | 0 |
| 30 Jun 17 | 0 | -2 | 2 | 0 |
| 31 Mar 17 | 0 | -1 | 1 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
Quality Earnings: NDVA is currently unprofitable.
Growing Profit Margin: NDVA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NDVA is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.
Accelerating Growth: Unable to compare NDVA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NDVA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: NDVA has a negative Return on Equity (-1869.99%), as it is currently unprofitable.